Compare Moderna, Inc. (MRNA) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Global X Defense Tech ETF — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Global X Defense Tech ETF trades at $60.14. The key difference: Moderna, Inc. is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | SHLD | |
|---|---|---|
Market Cap | $23.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $81.80 | $78.02 |
52-Week Low | $22.36 | $58.20 |
Enterprise Value | $19.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
SHLD trades at $60.03, down slightly by 0.05% with a bearish technical signal from moving averages. The ETF offers exposure to global defense technology companies amid rising military spending trends. Recent news highlights institutional buying interest and geopolitical tailwinds supporting the sector's growth outlook.
The defense technology theme benefits from increased global budgets, but SHLD faces competition from other defense ETFs and valuation concerns. Near-term technical support at $59 could stabilize declines, while resistance at $61 may cap upside. Risks include political shifts and execution challenges among holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
